Bristol/Otsuka aripiprazole "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA deems Bristol-Myers Squibb/Otsuka's schizophrenia treatment aripiprazole (new proposed tradename Abilify) "approvable" August 30. The aripiprazole NDA was submitted October 31, 2001. The firms expect approval of the atypical antipsychotic before the end of 200